Skip to main content
Fig. 17 | Cancer Nanotechnology

Fig. 17

From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 17

Histopathology of the control group (liver: A1, heart: A2, brain: A3, kidney: A4, lung: A5, and before tumour area: A6), prostate cancer group (B1 to B6) showed very mild metastasis (non-significant) in the liver (B1) and kidney (B4), but tumour foci with blood vessel were significant in tumour side (B6)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us